Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19

Drug Metabolism and Disposition

Volumn 31, Issue 10, 2003, Pages 1255-1259

  Yu, Bang Ning ^a   Chen, Guo Lin ^a   He, Nan ^a   Ouyang, Dong Sheng ^a   Chen, Xiao Ping ^a   Liu, Zhao Qian ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; N DEMETHYLASE; NORCITALOPRAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CITALOPRAM; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC;

EID: 0141569602     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.10.1255     Document Type: Article

References (26)

1. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, and Flockhart DA (1795) The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 57:662-629.
2. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, and Sjoqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylation of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51:388-397. Erratum in Clin Pharmacol Ther (1994) 55:648.
3. Broly F, Gaedigk A, Helm M, Eichelbaum M, Morike K, and Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558.
4. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, and Goldstein JA (1994a) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598.
5. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, and Goldstein JA (1994b) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422.
6. Dravet C, Mesdjian E, Cenraud B, and Roger J (1977) Interaction between carbamazepine and triacetyloleandomycin [letter]. Lancet 1:810-811.
7. Feng HJ, Huang SL, Wang W, and Zhou HH (1998) The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 45:27-29.
8. Ferguson RJ, de Marais SM, Benhamou S, Bouchardy C, Blaisdell J, and Ibeanu G (1998) A novel defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361.
9. Gonzalez FJ (1990) Molecular genetics of the P-450 superfamily. Pharmacol Ther 45:1-38.
10. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, Liao CL, and Zhang LM (1989) Metoprolol and mephenytoin oxidation polymorphism in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198-207.
11. Hyttel J (1982) Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6:277-295.
12. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, and Blaisdell J (1998) Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286:1490-1495.
13. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, and Kuroiwa Y (1997) Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 280:927-933.
14. Küpfer A and Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753-759.
15. Milne RJ and Goa KL (1991) Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41:450-477.
16. Olesen OV and Linnet K (1996) Simplified high-performance liquid chromatographic method for the determination of citalopram and desmethylcitalopram in serum without interference from commonly used psychotropic drugs and their metabolites. J Chromatogr B Biomed Appl 675:83-88.
17. Olesen OV and Linnet K (1999) Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes, Pharmacology 59:298-309.
18. Pessayre D, Konstantinova-Mitcheva M, Descatoire V, Cobert B, Wandscheer JC, Level R, Feldmann G, Mansuy D, and Benhamou JP (1981) Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration. Biochem Pharmacol 30:559-564.
19. Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, and Zhou HH (1999) Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 66:642-646.
20. Rochat B, Amey M, Gillet M, Meyer UA, and Baumann P (1997) Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7:1-10.
21. Sindrup SH, Brosen K, Hansen MG, Aaes-Jorgensen T, Overo KF, and Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15:11-17.
22. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, and Zhou HH (2001) Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 70:42-47.
23. Wang JS, Wang W, Xie HG, Huang SL, and Zhou HH (1997) Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. Br J Clin Pharmacol 44:195-198.
24. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, and Guzelian PS (1989) Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Investig 83:688-697.
25. Watkins PB, Turgeon DK, and Saenger P (1992) Comparison of urinary 6β-cortisol and the erythromycin breath test as measures of hepatic P450 3A (CYP3A) activity, Clin Pharmacol Ther 52:265-273.
26. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, and Zhou HH (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281:604-609.